Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
A new study links the diabetes drug metformin to fewer cases of pancreatic cancer — at least in women — but finds other diabetes medications are associated with a higher risk of the disease.…
Read More »Efficacy and Safety of Bydureon Versus Metformin, Pioglitazone, and Sitagliptin as Monotherapy
In a once weekly injection of exenatide for Drug-Naive Patients with Type 2 Diabetes (DURATION-4) in a 26-week double-blind study they found that exenatide once weekly (EQW) was noninferior to metformin (MET) but not pioglitazone (PIO) and superior to sitagliptin (SITA) with regard to HbA1c reduction at 26 weeks….
Read More »Once-Weekly Exenatide Similar to Daily Metformin in Monotherapy for Type 2 Diabetes
A direct comparison of four agents as monotherapy in drug-naive patients with type 2 diabetes shows that exenatide once-weekly, metformin, and pioglitazone provide good improvement in glycemic control, while sitagliptin is less effective.…
Read More »Should Metformin Be Used for Type 1 Diabetes?
The addition of off-label metformin to insulin therapy to improve insulin sensitivity, promote weight control, and reduce insulin dose requirements in patients with type 1 diabetes, has been assessed in systematic reviews.…
Read More »A Decade Later, Lifestyle Changes or Metformin Still Lower Type 2 Diabetes Risk
Study reports on persistence of benefits seen in the Diabetes Prevention Program
Read More »